company background image
688505 logo

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd SHSE:688505 Stock Report

Last Price


Market Cap







15 Jun, 2024


Company Financials

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

SHSE:688505 Stock Report

Market Cap: CN¥5.4b

688505 Stock Overview

Engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China.

688505 fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health6/6

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd
Historical stock prices
Current Share PriceHK$6.76
52 Week HighHK$10.71
52 Week LowHK$6.24
1 Month Change-10.11%
3 Month Change-15.18%
1 Year Change-21.67%
3 Year Change-62.19%
5 Year Changen/a
Change since IPO-81.73%

Recent News & Updates

Recent updates

Shareholder Returns

688505CN PharmaceuticalsCN Market

Return vs Industry: 688505 underperformed the CN Pharmaceuticals industry which returned -12.5% over the past year.

Return vs Market: 688505 underperformed the CN Market which returned -16.1% over the past year.

Price Volatility

Is 688505's price volatile compared to industry and market?
688505 volatility
688505 Average Weekly Movement5.1%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement6.7%
10% most volatile stocks in CN Market10.2%
10% least volatile stocks in CN Market4.2%

Stable Share Price: 688505 has not had significant price volatility in the past 3 months.

Volatility Over Time: 688505's weekly volatility (5%) has been stable over the past year.

About the Company

1996948Da Jun

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; DLL3-BB05 ADC that is in pre-clinical trials for tumors; and HER2 ADC that has carried out phase I clinical study for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Fundamentals Summary

How do Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's earnings and revenue compare to its market cap?
688505 fundamental statistics
Market capCN¥5.37b
Earnings (TTM)CN¥102.19m
Revenue (TTM)CN¥809.23m


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688505 income statement (TTM)
Cost of RevenueCN¥67.61m
Gross ProfitCN¥741.63m
Other ExpensesCN¥639.44m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 15, 2024

Earnings per share (EPS)0.099
Gross Margin91.65%
Net Profit Margin12.63%
Debt/Equity Ratio0%

How did 688505 perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.